Optimizing blood flow in patients on veno-venous ECMO
Official title: Reduction of Blood Recirculation in Veno-Venous ECMO Through Ultrasound Dilution Measurements (ECMO Circulation Study)
Run by Charite University, Berlin, Germany · NCT04754854 · Data updated 2026-11-12
This study is testing if adjusting blood flow during ECMO treatment can help patients with severe breathing problems get better oxygen without needing as much blood flow.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 136 (estimated) |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin) |
| Status | Recruiting |
| Started | November 20, 2020 |
| Main results expected | August 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | December 31, 2024 |
| Trial ID | NCT04754854 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 years or older who require veno-venous ECMO due to refractory hypoxemia from ARDS.
✕Probably not a fit
Patients who do not require veno-venous ECMO or those with conditions that preclude ECMO support may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to measure the recirculation fraction (Rf) of blood in patients with acute respiratory distress syndrome (ARDS) undergoing veno-venous ECMO. By utilizing an ultrasound dilution technique, the study will assess how optimizing ECMO blood flow based on Rf measurements can improve systemic oxygenation. The goal is to reduce ECMO blood flow without compromising patient oxygenation, potentially enhancing treatment outcomes for those on ECMO support.
Why it matters
Potential benefit: If successful, this approach could lead to improved oxygenation and reduced complications for patients on veno-venous ECMO.
How similar studies have gone: Previous studies, such as the 'Blood Recirculation and vvECMO' trial, have shown promising results in optimizing ECMO blood flow, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Where it's running
-
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
Berlin, Germany Recruiting
Study contacts
- Principal investigator: Martin Russ, Dr. med. — Charite University Hospital Berlin
- Study coordinator: Steffen Weber-Carstens, Prof. Dr. med.
- Email: steffen.weber-carstens@charite.de
- Phone: 0049-30450651005
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the impact of transpulmonary mechanical power on patients with severe ARDS on ECMO
This study is trying to see if measuring the power of breathing machines can help doctors predict how well patients with severe lung problems on ECMO will do and improve their treatment.
-
Full-Course ECMO Pathway for Moderate-to-Severe ARDS
This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.
-
Height measurement methods to guide ventilator settings in ARDS
We’re testing whether more precise height measurements change how researchers set lung-protective tidal volumes in adults with ARDS who are on a ventilator.
-
Corticosteroids for a hyperinflammatory state in critical illness
This trial tests whether methylprednisolone helps improve organ function and survival in adults with sepsis or ARDS who show a hyperinflammatory profile.
-
Right‑heart function and heart–lung interaction during ARDS with mechanical ventilation
This project will follow adults with ARDS on mechanical ventilation to see how positive‑pressure breathing affects the right heart over time and how that relates to circulation.
-
Umbilical‑cord mesenchymal stem cell and secretome therapy for severe ARDS
This trial tests whether IV umbilical‑cord mesenchymal stem cells, alone or with secretome, help adults with severe ARDS recover lung function and reduce inflammation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.